InMed Pharmaceuticals Inc (INM) insider trading

Every open-market stock purchase and sale by InMed Pharmaceuticals Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • ADAR1 Capital Management LLC (10% owner) bought $204K in the last 90 days, growing their stake 7%.

Last 12 months: insiders bought $1M (10 buys) and sold $0 (0 sales). Last close $1.33 on Oct 22, 2026.

Recent INM insider trades

DateInsiderTradeValue
Oct 19, 2026ADAR1 Capital Management LLC (10% owner)Bought$1.4K
Oct 16, 2026ADAR1 Capital Management LLC (10% owner)Bought$1
Oct 15, 2026ADAR1 Capital Management LLC (10% owner)Bought$1.3K
Oct 14, 2026ADAR1 Capital Management LLC (10% owner)Bought$10.7K
Oct 13, 2026ADAR1 Capital Management LLC (10% owner)Bought$750
Oct 8, 2026ADAR1 Capital Management LLC (10% owner)Bought$3K
Oct 7, 2026ADAR1 Capital Management LLC (10% owner)Bought$4.1K
Oct 6, 2026ADAR1 Capital Management LLC (10% owner)Bought$7.4K
Oct 5, 2026ADAR1 Capital Management LLC (10% owner)Bought$24.2K
Oct 2, 2026ADAR1 Capital Management LLC (10% owner)Bought$11K
Oct 1, 2026ADAR1 Capital Management LLC (10% owner)Bought$21.8K
Sep 16, 2026ADAR1 Capital Management LLC (10% owner)Bought$10.8K
Sep 15, 2026ADAR1 Capital Management LLC (10% owner)Bought$70.4K
Sep 14, 2026ADAR1 Capital Management LLC (10% owner)Bought$36.9K
Jul 16, 2026Vivo Opportunity LLC (10% owner)Bought$29
Jul 16, 2026Vivo Opportunity LLC (10% owner)Bought$3
Jul 15, 2026Vivo Opportunity LLC (10% owner)Bought$21.3K
Jul 15, 2026Vivo Opportunity LLC (10% owner)Bought$2.2K
Jul 15, 2026ADAR1 Capital Management LLC (10% owner)Bought$1.6K
Jul 14, 2026Vivo Opportunity LLC (10% owner)Bought$7.6K
Jul 14, 2026Vivo Opportunity LLC (10% owner)Bought$764
Jul 2, 2026Vivo Opportunity LLC (10% owner)Bought$2.3K
Jul 2, 2026Vivo Opportunity LLC (10% owner)Bought$228
Jul 1, 2026Vivo Opportunity LLC (10% owner)Bought$6.1K
Jul 1, 2026Vivo Opportunity LLC (10% owner)Bought$617

Who's trading INM

Get free alerts when an insider at InMed Pharmaceuticals Inc files a new trade →